5-甲基-n-[6-氯-5-(2-甲氧基苯氧基)-2-(4-吡啶)-4-嘧啶]-2-吡啶磺酰胺 | 290815-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-甲基-n-[6-氯-5-(2-甲氧基苯氧基)-2-(4-吡啶)-4-嘧啶]-2-吡啶磺酰胺
• 英文名称: 5-methyl-pyridine-2-sulfonic acid [6-chloro-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide
• 英文别名: 5-Methyl-N-[6-chloro-5-(2-methoxyphenoxy)-2-(4-pyridyl)-4-pyrimidinyl]-2-pyridinesulfonamide；N-[6-chloro-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
• CAS: 290815-30-4
• 化学式: C₂₂H₁₈ClN₅O₄S
• 分子量: 483.935
• InChiKey: JTVLWOPQTJTUHL-UHFFFAOYSA-N

物化性质

• 沸点：
  559.8±60.0 °C(Predicted)
• 密度：
  1.425±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  125
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-甲基-n-[6-氯-5-(2-甲氧基苯氧基)-2-(4-吡啶)-4-嘧啶]-2-吡啶磺酰胺 生成 N-[6-甲氧基-5-(2-甲氧基苯氧基)-2-(4-吡啶基)-4-嘧啶基]-5-甲基吡啶-2-磺酰胺
  参考文献：
  名称：

  Heterocyclic sulfonamides

  摘要：

  化合物式（I）中，R1的含义如描述中所给，是内皮素受体的抑制剂，因此可用于治疗与异常血管张力和内皮功能障碍相关的疾病。

  公开号：

  US06521631B2
• 作为产物：
  描述：

  5-Methyl-2-pyridine sulfonamide potassium salt 、 4,6-二氯-5-(2-甲氧基苯氧基)-2-吡啶-4-基嘧啶 生成 5-甲基-n-[6-氯-5-(2-甲氧基苯氧基)-2-(4-吡啶)-4-嘧啶]-2-吡啶磺酰胺
  参考文献：
  名称：

  Heterocyclic sulfonamides

  摘要：

  化合物式（I）中，R1的含义如描述中所给，是内皮素受体的抑制剂，因此可用于治疗与异常血管张力和内皮功能障碍相关的疾病。

  公开号：

  US06521631B2

文献信息

• The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists
  作者：Martin H Bolli、Christoph Boss、Martine Clozel、Walter Fischli、Patrick Hess、Thomas Weller

  DOI：10.1016/s0960-894x(02)01084-3

  日期：2003.3

  A series of compounds structurally related to bosentan 1 featuring an unsaturated side chain at position 6 of the core pyrimidine have been studied for their potential to block the ET(A) and ET(B) receptor. Incorporation of a 2-butyne-1,4-diol linker bearing a pyridyl carbamoyl moiety led to in vitro highly potent endothelin receptor antagonists (e.g., 70 and 75). The propargyl derivative 26 significantly

  研究了一系列与波生丹1结构相关的化合物，这些化合物在嘧啶核的6位上具有不饱和侧链，具有阻断ET（A）和ET（B）受体的潜力。掺入带有吡啶基氨基甲酰基部分的2-丁炔-1，4-二醇接头导致体外高效的内皮素受体拮抗剂（例如70和75）。在高血压盐敏感性Dahl大鼠的体内模型研究中，炔丙基衍生物26显着降低了血压。
• Butyne diol derivatives
  申请人：——

  公开号：US20030087920A1

  公开（公告）日：2003-05-08

  The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.

  本发明涉及一般式I的新型丁炔二醇衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备化合物的过程、含有一种或多种一般式I化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。
• 6 alkoxy-4-pyrimidinyl bis-sulfonamides
  申请人：Actelio Pharmaceuticals Ltd.

  公开号：US06596719B1

  公开（公告）日：2003-07-22

  The present invention relates to novel bis-sulfonamides represented, for example, by formula I below and a pure diastereomer, a mixture of diastereomers, a diastereomeric racemate, a mixture of diastereomeric racemates and meso-forms and a pharmaceutically acceptable salt thereof, wherein R1 represents aryl; aryl-lower alkyl; aryl-lower alkenyl; heteroaryl; or heteroaryl-lower alkyl; and R2 represents lower alkyl; trifluoromethyl; lower alkoxy-lower alkyl; lower alkenyl; lower alkynyl; aryl; aryl-lower alkyl; aryl-lower alkenyl; heterocyclyl; heterocyclyl-lower alkyl; heteroaryl; heteroaryl-lower alkyl; cycloalkyl; or cycloalkyl-lower alkyl. The present invention also relates to a process for manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the invention.

  本发明涉及一种新型双磺酰胺，例如以下式I所示的双磺酰胺及其纯对映异构体、对映异构体混合物、对映异构体外消旋体混合物和中间体形式以及其药学上可接受的盐，其中R1代表芳基；芳基-较低烷基；芳基-较低烯基；杂环芳基；或杂环芳基-较低烷基；R2代表较低烷基；三氟甲基；较低烷氧-较低烷基；较低烯基；较低炔基；芳基；芳基-较低烷基；芳基-较低烯基；杂环基；杂环基-较低烷基；杂环芳基；杂环芳基-较低烷基；环烷基；或环烷基-较低烷基。本发明还涉及一种制造这些化合物的方法，以及含有该化合物作为内皮素拮抗剂的制药组合物和使用本发明化合物治疗涉及内皮素的疾病的方法。
• Bis-sulfonamides as endothelin receptor antagonists
  作者：Christoph Boss、Martin H Bolli、Thomas Weller、Walter Fischli、Martine Clozel

  DOI：10.1016/s0960-894x(02)01083-1

  日期：2003.3

  Modification of the structure of bosentan 1, the first marketed endothelin receptor antagonist (Tracleer(TM)), by introduction of a second sulfonamide function at the alkoxy side chain, led to bis-sulfonamides 2. This allowed to prepare dual ETA/ETB as well as ETB receptor selective antagonists, which could serve as tools to investigate the pharmacological consequences of selective ETB receptor blockade. (C) 2003 Elsevier Science Ltd. All rights reserved.
• BIS-SULFONAMIDES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1137642A1

  公开（公告）日：2001-10-04